NIIMBL Funds Eight New Biopharma Technology and Workforce Projects
NIIMBL has selected eight new member-led technology and workforce development projects totaling $9.7 million in funding and co-investment through its Project Call 9.1, announced in a press release. The initiative involves 39 participating organizations focused on improving domestic biopharmaceutical manufacturing and workforce capabilities.
The technology projects address areas such as process analytics, AI and machine learning for process optimization, and new protein expression platforms for advanced therapeutics. Participants include universities and industry partners such as Michigan Technological University, University of Delaware, Massachusetts Institute of Technology, and several major biopharma companies.
Three workforce projects aim to expand interest in biopharmaceutical manufacturing careers and develop an AI-ready workforce. These include initiatives led by the University City Science Center, the National Center for Therapeutics Manufacturing at Texas A&M University, and The Wistar Institute.
Since its launch in 2017, NIIMBL has supported 230 technical and workforce projects totaling more than $216 million. The institute operates as part of Manufacturing USA, funded through a cooperative agreement with the National Institute of Standards and Technology.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Enterprise
Nov 20 Danaher and Microsoft build an agentic platform for lab instruments Nov 20 BlackLine brings OpenAI models to its finance operations platform with agent controls Nov 19 AWS Marketplace lets AI agents research and buy software, with optional pre-approved purchases Nov 19 Globant's AI Pods run rate more than doubles to $106.6 million as Q3 revenue dips 1% Nov 19 Anthropic offers credits of up to $2,000 per user to push its newer AI productsMore from Life Sciences
Nov 20 Danaher and Microsoft build an agentic platform for lab instruments Nov 19 Knit Health raises $35 million to roll out its healthcare world model Nov 19 Banner Health invests in Layer Health and moves its clinical registries onto its AI platform Nov 19 Half of Koreans who changed medication on AI advice had side effects, survey finds Nov 19 Isomorphic Labs and MSD team up to design cancer drugs with AILife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Boltz raises $110 million to build AI models for drug design
BioMap Announces 11 AI Life Science Collaborations
Formation Bio Forms $600 Million Drug Development Fund
Phylo Brings Biomni Lab AI Agents to Bayer
BioStack Raises $9.5 Million for Medical AI Data Network
Daily AI Brief: the AI news that matters, in your inbox.